# Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/GERN/geron-to-participate-in-the-goldman-sachs-47th-annual-global-healthcare-conferen-924410f0
Ticker: GERN
Company: Geron
Source: Geron
Published: 2026-06-01 12:00 EST
## Summary

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change...

## Article Body
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47 th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, FL.

A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com .

About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO ® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn .

Investors and Media Dawn Schottlandt Senior Vice President, Investor Relations and Corporate Affairs dschottlandt@geron.com
## Recent Company News
- 2026-07-22 20:01 EST — [Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-31c72267) — Source: Geron
- 2026-07-22 11:00 EST — [Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026](https://biopharmsignal.com/news/GERN/geron-plans-to-announce-second-quarter-2026-financial-results-on-august-5-2026-cc0edc91) — Source: Geron
- 2026-07-14 20:26 EST — [Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GERN/geron-corporation-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-dee5e3ab) — Source: Geron
- 2026-07-13 12:00 EST — [Geron Announces Appointment of Chinmaya Rath as Chief Business Officer](https://biopharmsignal.com/news/GERN/geron-announces-appointment-of-chinmaya-rath-as-chief-business-officer-bb96f9cb) — Source: Geron
- 2026-06-18 20:01 EST — [Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-09abd3e0) — Source: Geron
## Related News
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)
- 2026-07-28 12:05 EST — GSK — [GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK](https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859)